Literature DB >> 1148536

Proceedings: Hypotensive action of alpha-methyldopamine.

L Finch, A Hersom, P Hicks.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1148536      PMCID: PMC1666599     

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


× No keyword cloud information.
  7 in total

1.  The effect of L-alpha-methyl DOPA and N-2-hydroxybenzyl-N-methyl hydrazine (NSD 1039) on the blood pressure of renal hypertensive rates.

Authors:  R A DAVIS; D J DRAIN; M HORLINGTON; R LAZARE; A URBANSKA
Journal:  Life Sci (1962)       Date:  1963-03

2.  In-vivo decarboxylation of alpha-methyl DOPA and alpha-methyl metatyrosine.

Authors:  A CARLSSON; M LINDQVIST
Journal:  Acta Physiol Scand       Date:  1962-01

3.  Impairment of sympathetic nerve responses by dopa, dopamine and their alpha-methyl analogues.

Authors:  J B Farmer
Journal:  J Pharm Pharmacol       Date:  1965-10       Impact factor: 3.765

4.  Central hypotensive effect of alpha-methyldopa.

Authors:  M Henning; P A van Zwieten
Journal:  J Pharm Pharmacol       Date:  1968-06       Impact factor: 3.765

5.  Central nervous alpha-adrenergic receptors and the mode of action of alpha-methyldopa.

Authors:  A Heise; G Kroneberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

6.  Further evidence for a central hypotensive action of alpha-methyldopa in both the rat and cat.

Authors:  L Finch; G Haeusler
Journal:  Br J Pharmacol       Date:  1973-02       Impact factor: 8.739

7.  SOME OBSERVATIONS ON THE PHARMACOLOGY OF ALPHA-METHYLDOPA.

Authors:  M D DAY; M J RAND
Journal:  Br J Pharmacol Chemother       Date:  1964-02
  7 in total
  1 in total

1.  Alpha-methyl-DOPA induced mydriasis in the cat. Relationship between pupillary response and the oculomotor perfusate concentration of methyldopa and its metabolites.

Authors:  T Gherezghiher; M C Koss; H D Christensen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-11       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.